Intellia – CRISPR Therapy Hits Phase 3 Endpoint
Intellia Therapeutics reported that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met its Phase 3 primary endpoint in hereditary angioedema, reducing swelling attacks by 87% versus placebo and advancing toward FDA submission.
